Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
32 participants
INTERVENTIONAL
2007-04-30
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of an Artificial Pancreas in Patients Undergoing Hepatic Resection
NCT00659698
Tight Glycemic Control by Artificial Pancreas
NCT00735228
Hybrid Closed-Loop System in Neurosurgical Perioperative Hyperglycemia: An Open RCT
NCT06909071
Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN)
NCT02216799
Hybrid Closed-Loop for Perioperative Glycemic Control in T2DM With Parenteral Nutrition
NCT07121504
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2
Thirty patients who underwent pancreatic resection for pancreatic neoplasm were prospectively randomized. Perioperative blood glucose levels were continuously monitored using an artificial endocrine pancreas (STG-22). Glucose levels were controlled using either the sliding scale method or the artificial pancreas.
Artificial Pancreas (STG-22)
safe tool
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Artificial Pancreas (STG-22)
safe tool
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* signs of distant metastasis
* respiratory, renal,or heart disease
* Patients provided written informed consent prior to enrollment
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kochi University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kochi University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Takehiro Okabayashi, MD
Role: STUDY_DIRECTOR
Kochi Medical School, Kochi University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kochi Medical School, Kochi University
Nankoku, Kohasu-Okocho, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TGC-AP-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.